| |
Septemeber 8-11, 2025 | Philadelphia, PA Where biotech breakthroughs meet pharma scale. Dive into dynamic discussions on translational science, dealmaking, and the innovation shaping the next generation of therapies. Register now to connect and collaborate. .png)
|
|
Today’s Big NewsJun 2, 2025 |
|
Monday, June 16, 2025 | 12pm ET / 9am PT Join a candid and informative discussion between precision medicine experts. They will share lessons learned and concrete opportunities to transform clinical trial design, execution and outcomes. Register now. 
|
|
| By Kevin Dunleavy In late April, when Sanofi revealed that it was selling a controlling stake in its consumer health business Opella for 10 billion euros, chief financial officer Francois Roger said that the French drugmaker would “explore external growth opportunities for bolt-on acquisitions.” Just five weeks later, Sanofi has made a deal few would describe as “bolt-on,” as it has bought out Blueprint Medicines for $9.5 billion. |
|
|
|
By Nick Paul Taylor Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading candidates in the hottest area of immuno-oncology. |
By James Waldron Regeneron is paying Hansoh Pharma $80 million upfront for a phase 3-stage GLP-1/GIP receptor agonist the companies believe can hold its own against Eli Lilly’s Zepbound. |
By Conor Hale The companies that make up this class of the Fierce 15 exemplify the idea of moving the field forward by using innovation to build upon what’s come before. |
|
Wednesday, June 11, 2025 | 11am ET / 8am PT Join us for a deep dive into the strategies and best practices for maximizing valuation by improving productivity in modern clinical trials. We'll discuss key ways to achieve tangible productivity gains, accelerate timelines, and avoid costly protocol amendments or clinical failures. Register now to learn expert tips for maximizing efficiency and effectiveness. 
|
|
By Darren Incorvaia The Trump administration's proposed funding cuts to the National Institutes of Health, including the National Cancer Institute, “would be devastating to the pace and progress of cancer research in America” if they are implemented, the CEO of the American Society of Clinical Oncology said in a May 30 statement. |
By Gabrielle Masson The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of Clinical Oncology conference largely isn’t reflecting that turmoil. |
By Angus Liu AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu looks poised to reach newly diagnosed patients, with efficacy data that live up to the pair’s previous “highly statistically significant” description. |
By Eric Sagonowsky Moderna has picked up its third FDA approval with the agency's endorsement of mNEXSPIKE. The approval covers the vaccine's use in people 65 and older and those ages 12 to 64 with risk factors for severe COVID. |
By Angus Liu Already boasting a strong foothold in metastatic triple-negative breast cancer, Gilead Sciences’ Trodelvy has produced positive data that could make the antibody-drug conjugate part of a new front-line standard of care. |
By Darren Incorvaia Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to shrunken tumors and improved survival, the company announced in a June 2 presentation at the American Society of Clinical Oncology Annual Meeting in Chicago. |
By Andrea Park Endo is taking advantage of June’s status as Men’s Health Month to encourage men to prioritize their physical, mental and sexual health. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we break down first-quarter Big Pharma earnings, recap the latest gene therapy developments and preview what’s ahead at ASCO. |
|
|---|
|
|
|
Tuesday, June 17, 2025 | 11am ET / 8am PT Join experts from NIBRT and Securecell AG to explore how advanced Process Analytical Technologies (PAT) are transforming bioprocessing. Register now. 
|
|
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
